newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

IMMX
  • Immix Biopharma priced an underwritten registered offering of 19,117,646 common shares at $5.10 per share.
  • The company also issued 490,196 pre-funded warrants to purchase common stock at $5.09 per warrant.
  • Gross proceeds from the offering are expected to reach $100 million before deducting underwriting discounts, commissions, and other expenses.
  • The offering is scheduled to close on or about December 9, 2025, subject to customary closing conditions.
  • Net proceeds will fund the development of NXC-201, working capital, and general corporate purposes.
  • Existing cash, cash equivalents, and expected CIRM grant disbursements are projected to sustain operations through mid-2027.
  • Morgan Stanley serves as the sole book-running manager, while Citizens Capital Markets and Mizuho act as co-managers.
  • The securities are offered under a Form S-3 shelf registration statement filed with the SEC on January 3, 2023.
  • ImmixBio is a global leader in treating relapsed/refractory AL Amyloidosis with its lead candidate NXC-201, a CAR-T cell therapy.
  • NXC-201 is currently being evaluated in the registrational multi-center NEXICART-2 study (NCT06097832).
  • NXC-201 holds Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation from the FDA and EMA.